Committee opinion No. 527: Personalized genomic testing for disease risk

Obstetrics and Gynecology

Volumn 119, Issue 6, 2012, Pages 1318-1319

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; GENETIC DISORDER; GENETIC RISK; GENETIC SCREENING; HEART DISEASE; HUMAN; NEOPLASM; PERSONALIZED GENOMIC TESTING; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; ARTICLE; ETHICS; GENETIC PREDISPOSITION; GENETICS; METHODOLOGY;

GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GUIDELINES AS TOPIC; HUMANS; INDIVIDUALIZED MEDICINE;

EID: 84861646533     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31825af3c6     Document Type: Review

References (2)

1. Khoury MJ, McBride CM, Schully SD, Ioannidis JP, Feero WG, Janssens AC, et al. The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Centers for Disease Control and Prevention. Genet Med 2009;11:559-67.
2. Direct-to-consumer marketing of genetic testing. ACOG Committee Opinion No. 409. American College of Obstetricians and Gynecologists. Obstet Gynecol 2008;111: 1493-4.